137 related articles for article (PubMed ID: 19693645)
1. Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder.
Bourke MG; Martin ST; O'Dwyer M; Hanaghan J; Bennani F; Barry MK
Ir J Med Sci; 2012 Jun; 181(2):285-7. PubMed ID: 19693645
[TBL] [Abstract][Full Text] [Related]
2. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
[TBL] [Abstract][Full Text] [Related]
3. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G
J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783
[TBL] [Abstract][Full Text] [Related]
4. The JAK2 V617F mutation and thrombosis.
Austin SK; Lambert JR
Br J Haematol; 2008 Nov; 143(3):307-20. PubMed ID: 19004076
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
6. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
Xavier SG; Gadelha T; Rezende SM; Zalcberg IR; Spector N
Int J Lab Hematol; 2011 Apr; 33(2):117-24. PubMed ID: 21118380
[TBL] [Abstract][Full Text] [Related]
7. The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature.
Jacobs J; Sharma D; Vnencak-Jones C
J Thromb Thrombolysis; 2022 Jan; 53(1):213-217. PubMed ID: 34240279
[TBL] [Abstract][Full Text] [Related]
8. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.
P'ng S; Carnley B; Baker R; Kontorinis N; Cheng W
Clin Gastroenterol Hepatol; 2008 Apr; 6(4):472-5. PubMed ID: 18328792
[TBL] [Abstract][Full Text] [Related]
9. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation.
Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M
Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418
[No Abstract] [Full Text] [Related]
10. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
[TBL] [Abstract][Full Text] [Related]
11. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.
Owens CD
J Vasc Surg; 2010 Jul; 52(1):205-7. PubMed ID: 20434300
[TBL] [Abstract][Full Text] [Related]
12. A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation.
Galati G; Gentilucci UV; Sansoni I; Spataro S; Di Matteo FM; Zardi EM; Grasso RF; Avvisati G; Afeltra A; Picardi A
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):233-6. PubMed ID: 19212214
[TBL] [Abstract][Full Text] [Related]
13. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
14. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses.
McMahon C; Abu-Elmagd K; Bontempo FA; Kant JA; Swerdlow SH
Am J Clin Pathol; 2007 May; 127(5):736-43. PubMed ID: 17439832
[TBL] [Abstract][Full Text] [Related]
15. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
Lamy M; Palazzo P; Agius P; Chomel JC; Ciron J; Berthomet A; Cantagrel P; Prigent J; Ingrand P; Puyade M; Neau JP
Cerebrovasc Dis; 2017; 44(3-4):97-104. PubMed ID: 28609766
[TBL] [Abstract][Full Text] [Related]
16. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
[TBL] [Abstract][Full Text] [Related]
17. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
19. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
20. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
